HHS to Back Regeneron’s Ebola Drug Development, Manufacturing Efforts
Regeneron Pharmaceuticals has landed a potential 23-month, $38 million contract from the U.S. Department of Health and Human Services to further develop the company’s experimental drug against Ebola virus. HHS’ Biomedical Advanced Research and Development Authority could provide $11.3 million in additional funds for Regeneron to produce alternative anti-Ebola monoclonal antibody drugs for clinical research […] More
